Tonix Pharmaceuticals and its subsidiary Tonix Medicines have signed an agreement for the acquisition of Upsher-Smith Laboratories’ two migraine products.
The US Food and Drug Administration (FDA)-approved products, Zembrace SymTouch (sumatriptan injection) 3mg and Tosymra (sumatriptan nasal spray) 10mg, are intended to treat adult patients with acute migraine irrespective of aura status, and offer migraine pain relief onset in just under 10 minutes.
Zembrace SymTouch is a sumatriptan autoinjector while Tosymra is a new intranasal sumatriptan product.
These products together generated sales of $23m in 2022.
Upsher-Smith is entitled to receive an upfront payment of $12m in cash from Tonix Medicines on the closure of the deal.
Tonix Medicines will make a payment of $3m in March 2024, or on completing the transition services period.
Upsher-Smith will also receive $10m in cash from Tonix Medicines on taking over specific product-linked inventories.
Tonix Pharmaceuticals CEO Seth Lederman stated: “Sumatriptan remains the acute migraine “gold standard” treatment for many patients and continues to represent the largest segment of the market in terms of unit sales.
“With migraine pain relief possible in as little as 10 minutes for some patients and convenient administration, we believe both Zembrace SymTouch and Tosymra are well-suited to address the unmet needs of patients using traditional or emerging oral acute migraine medications, particularly for rapid-onset treatment.”
In April 2022, Tonix Pharmaceuticals and Kansas State University in the US signed a preclinical research agreement to develop TNX-2300, a live virus vaccine for Covid-19.
Source link
#Tonix #acquire #UpsherSmiths #migraine #products
